Active, not recruitingPhase 3NCT02972840
A Study of BR Alone Versus in Combination With Acalabrutinib in Subjects With Previously Untreated MCL
Studying Mantle cell lymphoma
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- Acerta Pharma BV
- Intervention
- Acalabrutinib(drug)
- Enrollment
- 635 target
- Eligibility
- 65 years · All sexes
- Timeline
- 2017 – 2027
Study locations (30)
- Research Site, Tucson, Arizona, United States
- Research Site, Downey, California, United States
- Research Site, Santa Monica, California, United States
- Research Site, New Haven, Connecticut, United States
- Research Site, Washington D.C., District of Columbia, United States
- Research Site, Tallahassee, Florida, United States
- Research Site, West Palm Beach, Florida, United States
- Research Site, Marietta, Georgia, United States
- Research Site, Westwood, Kansas, United States
- Research Site, Louisville, Kentucky, United States
- Research Site, Ann Arbor, Michigan, United States
- Research Site, Rochester, Minnesota, United States
- Research Site, Kansas City, Missouri, United States
- Research Site, St Louis, Missouri, United States
- Research Site, Hackensack, New Jersey, United States
- +15 more locations on ClinicalTrials.gov
Collaborators
AstraZeneca
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT02972840 on ClinicalTrials.govOther trials for Mantle cell lymphoma
Additional recruiting or active studies for the same condition.
- RECRUITINGPHASE3NCT07377578A Study of Rocbrutinib Versus Investigator's Choice of BTK Inhibitors in Patients With Relapsed or Refractory Mantle Cell LymphomaGuangzhou Lupeng Pharmaceutical Company LTD.
- RECRUITINGPHASE2NCT07272499Orelabrutinib Plus Lisaftoclax and Rituximab in Untreated Mantle Cell Lymphoma With High-Risk DiseaseRuijin Hospital
- RECRUITINGPHASE2NCT07029737A Study to Evaluate Acalabrutinib, in Combination With the R-CHOP Standard of Care, for Previously Untreated Mantle Cell Lymphoma in SpainAstraZeneca
- RECRUITINGNANCT07257510Pomalidomide Plus Orelabrutinib and Zuberitamab in Untreated Mantle Cell LymphomaPeking University Third Hospital
- RECRUITINGPHASE2NCT06846489Acalabrutinib Plus Rituximab for the Treatment of Elderly or Low- to Intermediate-Risk Younger Untreated Mantle Cell LymphomaSun Yat-sen University
- RECRUITINGPHASE3NCT06742996A Study to Investigate the Efficacy and Safety of Sonrotoclax Plus Zanubrutinib Compared With Placebo Plus Zanubrutinib in Adults With Relapsed/Refractory Mantle Cell Lymphoma (CELESTIAL-RRMCL)BeOne Medicines
- RECRUITINGNCT06788652A Study of Patients With Relapsed/Refractory Mantle Cell Lymphoma Treated With Lisocabtagene Maraleucel in the Post-Marketing SettingJuno Therapeutics, Inc., a Bristol-Myers Squibb Company
- RECRUITINGPHASE2NCT06522386GATE1: A Multicenter Phase II Study of Pirtobrutinib, Rituximab and Venetoclax Combination Therapy for Patients With Previously Untreated Mantle Cell LymphomaM.D. Anderson Cancer Center